Medincell (XPAR:MEDCL) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell COGS-to-Revenue?

Medincell's Cost of Goods Sold for the six months ended in Sep. 2023 was €0.00 Mil. Its Revenue for the six months ended in Sep. 2023 was €6.99 Mil.

Medincell's COGS to Revenue for the six months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Medincell's Gross Margin % for the six months ended in Sep. 2023 was N/A%.

Medincell COGS-to-Revenue Historical Data

The historical data trend for Medincell's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell COGS-to-Revenue Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

0.05

0.34

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial										-	-	-	-	-

Medincell COGS-to-Revenue Calculation

Medincell's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	9.944
	=	0.00

Medincell's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	6.985
	=	0.00

Medincell (XPAR:MEDCL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Medincell's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 6.985
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Medincell COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medincell's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines